Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2008, p. 1545-1548, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01284-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors
Delphine Desbois,1
Bénédicte Roquebert,1
Gilles Peytavin,2
Florence Damond,1
Gilles Collin,1
Antoine Bénard,5
Pauline Campa,4
Sophie Matheron,3
Geneviève Chêne,5
Françoise Brun-Vézinet,1
Diane Descamps,1* for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France,1
Laboratoire de Toxicologie, Service de Pharmacie, Hôpital Bichat-Claude Bernard, Paris, France,2
Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France,3
Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France,4
ISPED, Université Victor Segalen Bordeaux 2, INSERM U593, Bordeaux, France5
Received 4 October 2007/
Returned for modification 19 November 2007/
Accepted 14 January 2008
We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.
* Corresponding author. Mailing address: Laboratoire de Virologie, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France. Phone: 33 1 40 25 61 54. Fax: 33 1 40 25 67 69. E-mail:
diane.descamps{at}bch.aphp.fr
Published ahead of print on 28 January 2008.
Antimicrobial Agents and Chemotherapy, April 2008, p. 1545-1548, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01284-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Camacho, R. J., Wainberg, M. A.
(2009). Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2. Antimicrob. Agents Chemother.
53: 3611-3619
[Full Text]
-
Descamps, D., Lambert-Niclot, S., Marcelin, A.-G., Peytavin, G., Roquebert, B., Katlama, C., Yeni, P., Felices, M., Calvez, V., Brun-Vezinet, F.
(2009). Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother
63: 585-592
[Abstract]
[Full Text]
-
Roquebert, B., Damond, F., Collin, G., Matheron, S., Peytavin, G., Benard, A., Campa, P., Chene, G., Brun-Vezinet, F., Descamps, D., on behalf of the French ANRS HIV-2 Cohort (ANRS CO,
(2008). HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother
62: 914-920
[Abstract]
[Full Text]